Delhi-based experts are observing that many young people are opting for such treatments while looking for prospective matches and ahead of their wedding day

Certainly not GLP-1 drugs, who are now set to go mainstream. As the patent expires, the Indian markets will be flush with low-cost options. But, experts warn, indiscriminate jab-hopping may cost you more than you think